
The goal of the **Charge Master Assessment** is to provide a no cost or obligation review of the quality of coding, compliance and pricing within a hospital's charge master.

The **Charge Master Assessment** is a 4-phase process:

- 1. Processing of charge master and usage stats into the PARA Data Editor
- 2. Assignment of peer market group of hospitals
- 3. Reviewing assessment points using PDE filters
- 4. Presentation and review of Assessment findings

The **PARA Data Editor** is utilized in each phase of the assessment.



### Phase 1 - Processing of charge master and usage stats into the PARA Data Editor


PARA will establish the hospital charge master and usage stats into the

PDE. The PARA Data Requirements link is pasted below.

**PARA Data File Specification** 

The hospital data tables are submitted using the secured **PARA** File Transfer, a link to the instructions is pasted below.

https://apps.para-hcfs.com/para/Documents/PARA File Transfer User Guide 2017.pdf




Copyright © 2015 Peter A. Ripper & Associates, Inc. | webmaster@para-hcfs.com | Privacy Policy
CPT is a registered trademark of the American Medical Association

### Phase II - Assignment of peer market group of hospitals

**PARA** will link 9 peer hospitals to your Hospital for an analysis of pricing. There is an option to have three different market groups assigned and the User can update market groups and select market groups for all **Market Data Pricing Reports.** The market groups are as follows:

- 1. Geographic
- 2. Organizational
- 3. Service


The PDE Market Group Assignment Process will be utilized in this process.



Copyright © 2015 Peter A. Ripper & Associates, Inc. | webmaster@para-hcfs.com | Privacy Policy
CPT is a registered trademark of the American Medical Association

### Phase II - Assignment of peer market group of hospitals (continued)

The **PDE Market Pricing Data Tab** is can also be accessed by the User to review prices and charge capture.



### Phase II - Assignment of peer market group of hospitals (continued)

Demonstration Hospital Claim Summary Outpatient Medicare Limited Data Set -						et - Calendar \	ear 2015
Geographic	Market Group				20	017 ADDB Que	ry: 45378
HCPCS Code	Description	APC Status	Reimburse	ement	Hospital	Peer Group	National
45378	COLONOSCOPY, FLEXIBLE; DIAGNOSTIC, INCLUDING COLLECTION OF SPECIMEN(S) BY BRUSHING OR WASHING, WHEN PERFORMED (SEPARATE PROCEDURE)	т	667.67	APC	233	Total Claims Peer Claims Hospital Claim	s
00810	ANESTHESIA FOR LOWER INTESTINAL ENDOSCOPIC PROCEDURES, ENDOSCOPE INTRODUCED DISTAL TO DUODENUM	N					1.5 %
36415	COLLECTION OF VENOUS BLOOD BY VENIPUNCTURE	Q4	3.00	CLAB		1.7 %	7.9 %
70450	COMPUTED TOMOGRAPHY, HEAD OR BRAIN; WITHOUT CONTRAST MATERIAL	Q3	112.73	APC	9.1 %		0.1 %
74022	RADIOLOGIC EXAMINATION, ABDOMEN; COMPLETE ACUTE ABDOMEN SERIES, INCLUDING SUPINE, ERECT, ANDIOR DECUBITUS VIEWS, SINGLE VIEW CHEST	Q1	112.73	APC	9.1 %		0.2 %
80048	BASIC METABOLIC PANEL (CALCIUM, TOTAL) THIS PANEL MUST INCLUDE THE FOLLOWING: CALCIUM, TOTAL (82310) CARBON DIOXIDE (BICARBONATE) (82374) CHLORIDE (82435) CREATININE (82565) GLUCOSE (82947) POTASSIUM (84132) SODIUM (84295) UREA NITROGEN (BUN) (84520)	Q4	11.60	CLAB	9.1 %	0.4 %	4.3 %
80053	COMPREHENSIVE METABOLIC PANEL THIS PANEL MUST INCLUDE THE FOLLOWING: ALBIMIN (2000) BIRUBIN, TOTAL (2021/) CARBON DIOXIDE (BICARBONATE) (20274) CHACIDIN, TOTAL (2021) CARBON DIOXIDE (BICARBONATE) (20274) CHACIDINE (20235) CREATININE (20255) CALLOCE (20247) PHOSPHATASE, ALKALINE (20075) POTASSIUM (84132) PROTEIN, TOTAL (84155) SODIUM (84295) TRANSFERASE, ALANINE AMINO (AST) (50077) (34450) UREA NITROGEN (BUN) (34520)	Q4	14.49	CLAB		3.2 %	3.6 %
80076	HEPATIC FUNCTION PANEL THIS PANEL MUST INCLUDE THE FOLLOWING: ALBUMIN (82040) BILIRUBIN, TOTAL (82247) BILIRUBIN, DIRECT (82246) PHOSPHATASE, ALKALINE (84075) PROTEIN, TOTAL (84155) TRANSFERASE, ALANINE AMINO (ALT) (SGPT) (84460) TRANSFERASE, ASPARTATE AMINO (AST) (SGOT) (84450)	Q4	11.21	CLAB	9.1 %		0.4 %
81001	URINALYSIS, BY DIP STICK OR TABLET REAGENT FOR BILIRUBIN, GLUCOSE, HEMOGLOBIN, KETONES, LEUKOCYTES, NITRITE, PH, PROTEIN, SPECIFIC GRAVITY, UROBILINOGEN, ANY NUMBER OF THESE CONSTITUENTS; AUTOMATED, WITH MICROSCOPY	Q4	4.35	CLAB	9.1 %	2.2 %	0.8 %
82947	GLUCOSE; QUANTITATIVE, BLOOD (EXCEPT REAGENT STRIP)	Α	5.39	CLAB		1.1 %	2.1 %
82948	GLUCOSE; BLOOD, REAGENT STRIP	Q4	4.35	CLAB			2.6 %
82962	GLUCOSE, BLOOD BY GLUCOSE MONITORING DEVICE(S) CLEARED BY THE FDA SPECIFICALLY FOR HOME USE	Q4	2.47	CLAB	18.2 %	5.2 %	8.4 %
83690	LIPASE	Q4	9.45	CLAB	9.1 %	2.2 %	0.8 %
84132	POTASSIUM; SERUM, PLASMA OR WHOLE BLOOD	Q4	6.31	CLAB		0.4 %	1.3 %
84484	TROPONIN, QUANTITATIVE	Q4	13.50	CLAB	9.1 %	1.1 %	0.7 %
85014	BLOOD COUNT; HEMATOCRIT (HCT)	Q4	3.25	CLAB			1.8 %
85018	BLOOD COUNT; HEMOGLOBIN (HGB)	Q4	3.25	CLAB			1.5 %
85025	BLOOD COUNT; COMPLETE (CBC), AUTOMATED (HGB, HCT, RBC, WBC AND PLATELET COUNT) AND AUTOMATED DIFFERENTIAL WBC COUNT	Q4	10.66	CLAB	9.1 %	0.4 %	5.3 %
85027	BLOOD COUNT; COMPLETE (CBC), AUTOMATED (HGB, HCT, RBC, WBC AND PLATELET COUNT)	Q4	8.87	CLAB		0.9 %	2.7 %
85610	PROTHROMBIN TIME	Q4	5.39	CLAB	9.1 %	0.4 %	4.5 %
85730	THROMBOPLASTIN TIME, PARTIAL (PTT); PLASMA OR WHOLE BLOOD	Q4	8.24	CLAB	9.1 %	0.4 %	2.3 %
86850	ANTIBODY SCREEN, RBC, EACH SERUM TECHNIQUE	Q1	39.70	APC		0.4 %	1.4 %
86900	BLOOD TYPING, SEROLOGIC; ABO	Q1	54.55	APC		1.1 %	1.4 %
86901	BLOOD TYPING, SEROLOGIC; RH (D)	Q1	28.38	APC		0.4 %	1.4 %
87081	CULTURE, PRESUMPTIVE, PATHOGENIC ORGANISMS, SCREENING ONLY	Q4	9.09	CLAB	9.1 %		0.4 %


Confidential - Protected by the PARA/Hospital Disclosure Agreement CPT is a registered trademark of the American Medical Association

Run Date: 8/8/2017 Page 1 of 3 Peter A. Ripper & Associates, Inc. http://www.para-hcfs.com


The reports are available in PDF or worksheet formats.

#### Phase III - Reviewing assessment points using PDE filters

The process utilized for the review is driven by the **Filters Tab** within the **PDE**.




The results of the filter query is reported in the **CDM Tab**:



### Phase III - Reviewing assessment points using PDE filters (continued)

The filters utilized in the **Charge Master Assessment** are as follows:

- 1. Invalid codes contained in the charge master
- 2. Compliance items (Wheatland Audit)
- 3. Items priced below clinical lab fee schedule
- 4. Gross Market Opportunity Revenue Market Average
- 5. Gross Market Opportunity Revenue 75<sup>th</sup> Percentile
- 6. Room Rate Opportunity
- 7. Medical DRG's Revenue per case
- 8. Surgical DRG's Revenue per case
- 9. Pharmacy Self Admin Drugs currently coded, code review
- 10. Pharmacy Self Admin Drugs to be reviewed, compliance review
- 11. Pharmacy Self Admin Drugs coded with a "J" code, for code review
- 12. Pharmacy Items coded with a "J" code
- 13. DME exempt hospital billable code review
- 14. DME possible exempt billable items, identified for review
- 15. HCPCS "C" coded items, code review
- 16. Blood processing and admin code review
- 17. Units of Service per ml/sq cm code and pricing review
- 18. Observation per hour, 24 hours equals semi rate



### Phase IV - Presentation and review of Assessment findings

PARA summarizes the finding into a worksheet for presentation and discussion with hospital staff.

		Coding Assessment					
	Demonstration Hospital CDM 11/29/16 (5,986 line items) Transaction Period: 11/1/2015 to 10/31/2016	Total Returns	Returns w/Qty	Comment			
	Query Description						
1	Invalid	473	209	Needs review			
2	Pharmacy - Self Admin Drugs to be reviewed	48	27	Needs review			
3	MAC Specific Self-Administered Drugs	4	2	Needs review			
4	Pharmacy – Chemo drugs appropriate for chemo admin charges	1	1	Needs reviev			
5	Pharmacy NDC Review	899	672	Needs review			
6	DME OPPS - Exempt	0	0	Needs review			
7	DME OPPS - Identified	37	10	Needs reviev			
8	C coded items	1,022	355	Needs reviev			
9	Blood - 038X, 039X rev codes and HCPCS	15	14	Needs reviev			
10	Units of Service per ml/sq cm	43	23	Needs reviev			
11	Observation per hour, 24 hours equals semi rate	6	4	Looks of			
		Pricing Assessment					
		Total Returns	Returns w/Qty	Comment			
	Query Description						
1	Priced below clinical lab fee schedule	378	240	Needs review			
2	GOR Market Opportunity Average (10% inflation)	n/a	n/a	1.24M Needs review			
3	GOR Market Opportunity 75 <sup>th</sup> Percentile (10% inflation)	n/a	n/a	1.662M Needs review			
4	Room Rates	11/ 0	,	Below Mkt Av			
5	Medical DRG's revenue per case			Below Mkt Av			
6	Surgical DRG's revenue per case			Below Mkt Avg			
			Compliance Assessment				
		Total Returns	Returns w/Qty	Comment			
	Query Description						
1	Query Description  Compliance items - Wheatland Audit	80	38	Needs review			